Evidence map›Paper›PMID 42726116›Full record

ReviewOrthopadie (Heidelberg, Germany)2026

[Antimicrobial therapy of periprosthetic joint infection : Summary of AE guidelines (2026)].

Susanne Feihl, S Meller, Y Gramlich, R von Eisenhart-Rothe, R Hube, P Radünzel, R Otchwemah, Gunnar Hischebeth

Abstract readEnglish AbstractReview
In one paragraph

Review in Orthopadie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Susanne FeihlAntimicrobial Stewardship, Technische Universität München, TUM School of Medicine and Health, TUM Klinikum, Ismaninger Straße 22, 81675, München, Deutschland. susanne.feihl@mri.tum.de.
S MellerCentrum für Muskuloskeletale Chirurgie, Charité-Universitätsmedizin Berlin, Berlin, Deutschland.
Y GramlichKlinik für Orthopädie und Unfallchirurgie, AGAPLESION Markus Krankenhaus, Frankfurter Diakonie Kliniken, Frankfurt am Main, Deutschland.
R von Eisenhart-RotheKlinik für Orthopädie und Sportorthopädie, Technische Universität München, TUM School of Medicine and Health, TUM Universitätsklinikum, München, Deutschland.
R HubeOrthopädische Chirurgie München (OCM), München, Deutschland.
P RadünzelCentrum für Muskuloskeletale Chirurgie, Charité-Universitätsmedizin Berlin, Berlin, Deutschland.
R OtchwemahAbteilung für Hygiene und Umweltmedizin, Universitätsmedizin Essen, Universität Duisburg-Essen, Essen, Deutschland.
Gunnar HischebethInstitut für Medizinische Mikrobiologie, Immunologie und Parasitologie (IMMIP), Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland. gunnar.hischebeth@ukbonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeriprosthetic joint infections (PJI) are among the most severe and complex complications following joint arthroplasty and require a structured interdisciplinary treatment approach. In addition to an adequate surgical strategy, pathogen-directed and patient-specific anti-infective therapy plays a central role in successful management.

methodsBased on a comprehensive literature review and current guidelines, followed by a structured consensus process within the interdisciplinary working group of the "German Society for Arthroplasty (Deutsche Gesellschaft für Endoprothetik e. V.)", available treatment options were evaluated and consensus recommendations for the anti-infective management of PJI were developed.

resultsThe cornerstone of PJI treatment is surgical management combined with an initial empiric followed by targeted antibiotic therapy. Staphylococci represent the most frequently identified pathogens, with the biofilm-active antibiotic rifampin playing a key role in their treatment. Fluoroquinolones are primarily used for infections caused by gram-negative pathogens but are also employed in combination with rifampin for staphylococcal infections. For other clinically relevant pathogen groups, differentiated consensus-based treatment recommendations were established. The recommended total duration of antibiotic therapy is generally approximately 12 weeks.

conclusionAnti-infective therapy represents a key component in the successful treatment of periprosthetic joint infections. An individualized therapeutic approach, tailored to the respective surgical treatment strategy, is essential.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsProsthesis-Related InfectionsGermanyHumansJoint ProsthesisAnti-Bacterial AgentsAnti-Infective AgentsAntiinfective agentsBiofilmConsensusDrug side effectsJoint prosthesis

Identifiers

PMID42726116
PMCPMC13601107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.